Research Glossary

GLP-1 vs GLP-1/GIP vs Triple Agonist — A Plain-English Glossary

By Synedica Labs Research Team · 5 May 2026 · 6 min read

Quick summary

What is a "receptor agonist"?

An agonist is a molecule that binds to a cellular receptor and activates it the same way the body's natural signal would. In metabolic research, the receptors of interest sit on cells in the gut, pancreas and central nervous system, and they regulate insulin release, appetite signalling and energy expenditure.

The three classes, side by side

ClassReceptors targetedReference compoundResearch interest
Mono-agonist (GLP-1) GLP-1 only Semaglutide Baseline GLP-1 reference, gold-standard incretin model
Dual agonist (GLP-1 + GIP) GLP-1 + GIP Tirzepatide Combined incretin pathway studies, comparator arm
Triple agonist (GLP-1 + GIP + Glucagon) GLP-1 + GIP + Glucagon Retatrutide Most recent class — energy expenditure + incretin combined

Why receptor count matters in study design

Receptor breadth changes the biological response. A mono-agonist isolates a single pathway, which is ideal for clean reference work. Dual and triple agonists activate parallel pathways simultaneously, which is closer to a real metabolic situation but harder to attribute mechanistically. Most well-designed comparative studies include all three classes as reference arms.

Common terms you will see in COAs and papers

How the three reference compounds compare in practice

For a deeper side-by-side, including bench notes and structural differences, read our dedicated comparison: Retatrutide vs Tirzepatide vs Semaglutide.

The shorthand "single, double, triple" is convenient but not the full picture — receptor affinity and selectivity vary hugely inside each class.
Where to go next

Related research reading

How to read a COA

Once you've picked a class, verify the supplier with the right paperwork.

FAQ

Glossary FAQ

Is a triple agonist always "better" than a mono-agonist?
Not in research terms. Triple agonists activate more pathways simultaneously, which can complicate mechanistic attribution. A mono-agonist isolates one pathway cleanly, which is preferable for reference work.
Why is GIP added to GLP-1 in dual agonists?
GIP is the second major incretin and acts on a parallel insulin-release pathway. Adding it broadens the metabolic response without leaving the incretin family.
What does adding the glucagon receptor change?
Glucagon receptor activation increases energy expenditure, which is mechanistically distinct from the incretin pathways and is the main reason triple agonists became a separate class of research interest.

Browse all research kits →